ALK G1202R
An ALK resistance change commonly discussed after second-generation inhibitors.
Parent marker: ALK
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
G1202R reduces the effectiveness of some ALK inhibitors, so the discussion shifts to drugs that are still active against this change or in clinical trials.
How this finding appears in a report
Checked through tissue or blood sequencing after progression.
When therapy stops working
The combination of additional changes and brain involvement is the next consideration.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: ALK
The presence of ALK fusion opens up a category of specific oral targeted therapies. ALK examination is generally carried out in conjunction with examination of other markers at the time of diagnosis of advanced stage non-small cell lung cancer.
A negative result does not always mean absent
Summary
- Gen
- ALK
- Variant
- ALK G1202R
- Alteration type
- Mutation
- Discussed in
- Lung Cancer
- Updated
- 2026-09-10
Other names in reports
G1202R
Drugs discussed
Treatment categories
Related guides
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- ALK
Biomarker
Reason: Related through a biomarker
- Lung Cancer
Cancer type
Reason: Related to this page
- Lorlatinib
Drug
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.